OCI-My5Homo sapiens (Human)Cancer cell line
Also known as: MY5, OCIMY5, OCIMy5, OCI-My 5, OCI-MY5
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_E332 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Male |
Disease Information
| Disease | Multiple myeloma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Plasma Cell Myeloma |
| OncoTree Code | PCM |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-000854_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Val73Trpfs*50 (c.216delC) (p.P72fs) | Heterozygous | - | Unknown, Unknown, PubMed=9887230 |
Loading gene expression data...
Publications
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Sirota M., Wiita A.P.
Leukemia 34:2754-2765(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of MYC translocations in multiple myeloma cell lines.
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Stewart A.K., Carpten J.D., Bergsagel P.L.
Cancer Cell 12:131-144(2007).
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Kuehl W.M., Bergsagel P.L.
Blood 97:729-736(2001).
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Drexler H.G., Matsuo Y.
Leuk. Res. 24:681-703(2000).
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Kuehl W.M.
Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: effect of different dose rates and fractionation.
Gluck S., Van Dyk J., Messner H.A.
Int. J. Radiat. Oncol. Biol. Phys. 28:877-882(1994).
Segregation of precursors with high proliferative potential from their differentiated progeny in a myeloma cell line.
Wandl U.B., Hoang T., Minden M.D., Messner H.A.
J. Cell. Physiol. 136:384-388(1988).
Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease.
Messner H.A.
Blood 78:1996-2004(1991).
Multiple myeloma cell lines.";
Jernberg-Wiklund H., Nilsson K.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).